DexCom raised its 2026 revenue and margin outlook after reporting stronger second-quarter results. The company now expects 2026 revenues of $5.18 to $5.25 billion, up from the prior $5.16 to $5.25 billion range, implying 11 to 13 percent annual growth. DexCom also lifted its adjusted gross margin forecast to about 64 percent, adjusted operating margin guidance to 23.5 to 24 percent, and adjusted EBITDA margin guidance to 31.5 to 32 percent. Second-quarter revenues rose 13.1 percent year over year to $1.31 billion, with adjusted operating income up 48 percent to $328.3 million and adjusted operating margin expanding to 25.1 percent. The company cited manufacturing efficiencies and the initial customer switchover to its G7 15 Day sensor as key drivers, and expects to convert nearly half of its U.S. customer base to that product by year-end 2026.
DexCom IncDexCom raised 2026 revenue and margin outlook after strong Q2, with revenue growth and margin expansion.
Abbott Laboratories
Senseonics Holdings, Inc. Common Stock